Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more
Ginkgo Bioworks Holdings (DNA) - Total Liabilities
Latest total liabilities as of December 2025: $611.11 Million USD
Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has total liabilities worth $611.11 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ginkgo Bioworks Holdings - Total Liabilities Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ginkgo Bioworks Holdings Competitors by Total Liabilities
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Niutech Environment Technology Corp
SHG:688309
|
China | CN¥176.46 Million |
|
Cadiz Inc
NASDAQ:CDZI
|
USA | $100.27 Million |
|
Tanseisha Co., Ltd.
PINK:TAHCF
|
USA | $18.55 Billion |
|
Zhejiang Huilong New Materials Co.Ltd.
SHE:301057
|
China | CN¥812.00 Million |
|
Formosa Advanced Technologies Co Ltd
TW:8131
|
Taiwan | NT$1.67 Billion |
|
GHT Co Ltd Class A
SHE:300711
|
China | CN¥538.80 Million |
|
CTOS Digital Bhd
KLSE:5301
|
Malaysia | RM211.19 Million |
|
Allscripts Healthcare Solutions Inc
STU:AL21
|
Germany | €513.64 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Ginkgo Bioworks Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ginkgo Bioworks Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual total liabilities of Ginkgo Bioworks Holdings from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $611.11 Million | -7.60% |
| 2024-12-31 | $661.39 Million | +16.40% |
| 2023-12-31 | $568.19 Million | -29.25% |
| 2022-12-31 | $803.04 Million | +59.46% |
| 2021-12-31 | $503.61 Million | +145.54% |
| 2020-12-31 | $205.10 Million | +4.93% |
| 2019-12-31 | $195.47 Million | -- |